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Abstract
Sapru et al. show in this issue of Critical Care that
variants of thrombomodulin and the endothelial
protein C receptor, but not protein C, are associated
with mortality and organ dysfunction (ventilation-free
and organ failure-free days) in ARDS. Hundreds of
gene variants have been found prognostic in sepsis.
However, none of these prognostic genomic
biomarkers are used clinically. Predictive biomarker
discovery (pharmacogenomics) usually follows a
candidate gene approach, utilizing knowledge of drug
pathways. Pharmacogenomics could be applied to
enhance efficacy and safety of drugs used for
treatment of sepsis (e.g., norepinephrine, epinephrine,
vasopressin, and corticosteroids). Pharmacogenomics
can enhance drug development in sepsis, which is
very important because there is no approved drug for
sepsis. Pharmacogenomics biomarkers must pass three
milestones: scientific, regulatory, and commercial. Huge
challenges remain but great opportunities for
pharmacogenomics of sepsis are on the horizon.
This issue of Critical Care presents a novel human gen-
omics study showing that variants of thrombomodulin
(TM) and the endothelial protein C receptor (EPCR),
but not protein C, are associated with mortality and organ
dysfunction (ventilation-free and organ failure-free days) in
ARDS—that is, they are prognostic biomarkers [1].
Strengths include the cohort, gene, and variant selections,
Hardy–Weinberg equilibrium, correlation of variants with
plasma protein levels, correction for multiple comparisons,
a haplotype model, a multivariant approach, and a priori
sample size calculation. A relative weakness was the
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reliance on literature for biological plausibility of the
“significant” variants. These innovative insights could lead
to “predictive biomarkers” for response to recombinant
human TM and even activated protein C (APC) in sepsis.
Genomics and pharmacogenomics (PGx) are pivotal to
fields such as cancer and cardiovascular medicine. In
cancer, PGx biomarker(s) include trastuzumab (Hercep-
tin, HER2), irenotecan (UGT1A1*28), azothioprine and
6-mercaptopurine (TPMT), capecitabine (dihydropyri-
midine dehydrogenase), and cetuximab/panitumumab
(KRAS)—these drugs are very frequently given according
to the specific PGx biomarker. In cardiovascular medicine,
clopidogrel (CYP2C19) and warfarin (VKORC1) are well-
documented PGx biomarkers that indicate altered efficacy
and safety respectively. PGx biomarkers are used increas-
ingly in clinical practice.
Sepsis has gone through 15 years of discovery of many
genomic biomarkers [2, 3]. A PubMed search for “sepsis
and polymorphism” yields 1199 publications. Let us de-
fine some terminology: a prognostic biomarker identifies
prognosis (e.g., increased risk of death); a diagnostic bio-
marker diagnoses condition (e.g., sepsis diagnostic); and
a predictive biomarker (companion diagnostic) uses
genomics to define response to a drug (see http://www.fda.
gov/MedicalDevices/ProductsandMedicalProcedures/InVi-
troDiagnostics/ucm407297.htm). Over 100 drugs have ap-
proved predictive biomarkers on the drug label (http://
www.fda.gov/drugs/scienceresearch/researchareas/pharma-
cogenetics/ucm083378.htm)!
About one quarter of the human genome changes ex-
pression in sepsis [4], so it is not surprising that hun-
dreds of variants are described in sepsis [3]. However,
none of these prognostic genomic biomarkers are used
clinically, probably because of lack of clinical utility (i.e.,
the test result would not change a clinician’s behavior).
Nonetheless, genomics of sepsis studies have identified
key pathways associated with specific organ dysfunctions
and mortality, and have identified drug targets in sepsis
(e.g., proprotein convertase subtilisin/kexin type 9 (PCSK9)
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Table 1 Potential pharmacogenomic biomarkers and steps to discovery for drugs used clinically, drugs in development, and drugs
that could be resurrected in sepsis
Drugs in use clinically in sepsis and septic shock Potential pharmacogenomic biomarkers First step(s) to discovery/validation of PGx biomarkers
Norepinephrine (NE), epinephrine (EP),
dobutamine
ARs:
ADBR1 and ADBR2 [7] SNPs
ADRA1A and B SNPs
G-protein subunits (α, β, and γ) of ADR2a
α2A N251K and α2C Δ322-325 (common AR SNPs)
ADRA2A, B and C SNPs
ADCY9 SNPs
Genotyping of patients in RCT
(e.g., Annane et al. [8])
Vasopressin LNPEP SNPs [9],
AVPR1a, AVPR1b, and AVPR2 SNPs
Genotyping of patients in RCT
(e.g., Russell et al. [10])
Corticosteroids CRF SNPs
GRs [11]
GR heterocomplex gene STIP1 SNPs:
ER22/23EK (common GR SNP)
GR: N363S (common GR SNP)
GR: 9β A/G (common GR SNP)









Genotyping of patients in RCT
(e.g., Sprung et al. [12])
Examples of drugs used in sepsis that
have FDA-approved companion diagnostics
Diazepam CYP2C19 (poor metabolizers of diazepam) FDA labela
Methylene blue G6PD deficiency FDA labela
Omeprazole, pantoprazole CYP2C19 (poor metabolizers of Omeprazole and
pantoprazole)
FDA labela
Resperidone CYP2D6 (poor metabolizers of respiradone) FDA labela
Drugs in or near development
Thrombomodulin (TM) TM, EPCR [1], and Genotyping of patients in RCTb
PROC SNPs
Selepressin LNPEP SNPs [9],
AVPR1a SNPs
Genotyping of patients in RCTb
Angiotensin II (ANG II) AGT SNPs
AGTRAP SNPs [13]
ACE SNPs and ID
AT1R and 2R SNPs
Genotyping of patients in RCTb
PCSK9 inhibitor PCSK9 SNPs [5] Genotyping of patients in RCTb
IL-7 IL-7, IL-7ra SNPs Genotyping of patients in RCTb
Esmolol ADBR1A and B SNPs [7] Genotyping of patients in RCT
Resurrecting a drug
Activated protein C TM, EPCR [1]
PROC SNPs [14]
Genotyping of patients in RCT
(e.g., Ranieri et al. [15])
PGx pharmacogenomics, SNP single nucleotide polymorphism, RCT randomized controlled trial, AR adrenergic receptor
ADRA adrenergic alpha receptor, ADBR1/2 β1/2-adrenergic receptor, LNPEP leucyl/cystinyl aminopeptidase (vasopressinase), AVPR1a/b gene name for V1a/b
receptors, CRF corticotropin-releasing factor, ADCY9 adenylyl cyclase type 9, EPCR endothelial protein C receptor, PROC protein C, GR membrane-bound and
cytosolic glucocorticoid receptor, GLCCI1 glucocorticoid-induced transcript 1 gene, ABCB1 gene codes for P-glycoprotein, NR3C1 glucocorticoid receptor gene, MR
mineralocorticoid receptor, NALP1 NACHT leucine-rich-repeat protein 1, NK2R neurokinin receptor 2, CTLA4 anti-cytotoxic T lymphocyte-associated antigen-4, PCSK9
proprotein convertase subtilisin/kexin type 9, CYP2C19 cytochrome P450 2C19, G6PD glucose-6-phosphate dehydrogenase, AGT angiotensinogen gene, AGTRAP
angiotensin II receptor-associated protein, ACE angiotensin-converting enzyme, ID insertion/deletion polymorphisms, AT1/ 2R angiotensin-II type 1 and 2 receptor
gene, IL-7ra interleukin-7 receptor alpha chain
aThese markers are already approved for clinical use with shown drugs on the drug FDA label. No further RCTs are required for “on label” clinical use of the
companion diagnostic strategy in practice
bOverviews of RCTs of: thrombomodulin (https://clinicaltrials.gov/ct2/show/NCT01598831?term=thrombomodulin+in+sepsis&rank=2),
selepressin (https://clinicaltrials.gov/ct2/show/NCT02508649?term=selepressin+in+shock&rank=1)
angiotensin II, (https://clinicaltrials.gov/ct2/show/NCT01393782?term=angiotensin+II+in+septic+shock&rank=2), and
IL-7 (https://clinicaltrials.gov/ct2/show/NCT02640807?term=il-7+in+sepsis&rank=1)
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[5]). Variants of PCSK9 were associated with outcomes of
sepsis, and post treatment of cecal ligation and perforation
model mice with PCSK9 inhibitors decreased inflamma-
tion, cardiovascular dysfunction, and mortality; thus,
PCSK9 inhibition could be effective in sepsis [5]. This ex-
ample could be expanded to other genes and novel drugs.
Predictive biomarker discovery often follows a candi-
date gene approach, utilizing knowledge of drug recep-
tors, transporters, enzymes that metabolize a drug, and
drug target pathways. Predictive biomarkers often have
high clinical utility. FDA-approved drug labels have a
hierarchy of recommendations for companion diagnos-
tics: (1) for information (i.e., descriptions of published
studies of PGx related to the drug); (2) recommended—-
physicians are encouraged to measure the biomarker;
and (3) required—physicians MUST use the companion
diagnostic to prescribe the drug. The required companion
diagnostic relates to trastuzumab: HER2 must test positive
for identifying good responders to order trastuzumab.
The PGx biomarker discovery pathway is arduous, time-
consuming, and expensive. A successful PGx biomarker
must pass three milestones: scientific, regulatory, and
commercial. Scientific steps include: a decision regarding
a nonhypothesis-driven (genome-wide) vs a candidate
gene approach, RCTs, significant drug/PGx biomarker
interaction, validation often in a separate RCT, and valid-
ation of a rapid turnaround time (TAT) kit in real time.
The regulatory node includes many submissions and visits
to regulators before and after each study. Regulators have
approved PGx biomarkers in cancer that were assessed at
the end of pivotal RCTs provided that the biomarker hy-
pothesis was logged before locking the RCT dataset. Thus,
selection of PGx biomarkers may occur in parallel with
RCT execution. Finally, the commercial node includes
costs of kits, reimbursement methods and amounts,
FDA-approved and EMEA-approved manufacturing,
and distribution of a rapid TAT kit (and sometimes a
unique “box” for measuring the biomarker) to hospitals
(laboratories and/or ICUs or EDs).
PGx could be applied to enhance efficacy and safety of
drugs in use for sepsis and septic shock including nor-
epinephrine, epinephrine, vasopressin, and corticoste-
roids (CS) (Table 1); known genomic variants intersect
with these drugs. Genomics of the CS and vasopressin
(AVP) axes have been well studied for prediction of re-
sponse to CS (and less so vasopressin), because CS and
AVP variants are widely studied in many conditions and
because CS are used in so many conditions (Table 1).
PGx can also enhance drug development, very important
since there is no approved drug for sepsis. PGx could in-
crease chances of drug development success in sepsis; that
is, precision medicine to enrich the heterogeneous sepsis
cohorts [2, 6]. Potential predictive biomarkers/companion
diagnostics could be used with recombinant human TM,
selepressin, angiotensin II, PCSK9 inhibitor, IL-7, and
esmolol (Table 1). Studies of PGx of ACE inhibitors in car-
diovascular disease and IL-7 in cancer could inform angio-
tensin II and IL-7 PGx in sepsis (Table 1). Several drugs
used clinically in sepsis have proven companion diagnostics
(Table 1).
Finally, PGx could resurrect “dead” drugs by increasing
efficacy. APC could be resurrected by using genetic vari-
ants such as those discovered by Sapru et al. [1] that might
mark patients who have an enhanced response to APC to
enrich patient selection in a future RCT (Table 1).
In summary, there remain huge challenges but great
opportunities for genomics, and I think more import-
antly for PGx of sepsis. We are close—but yet so far be-
cause there are many complex steps and milestones to
bring a novel PGx biomarker to septic patients and their
caregivers. I remain very optimistic that researchers such
as Sapru et al. [1] and other scientists in the field are up
to the challenge!
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